TRxADE HEALTH Inc. (NASDAQ:MEDS) shares traded 27.89% higher at $0.37 on Wall Street last session.
In accordance with the data, 3 analysts cover TRxADE HEALTH Inc. (NASDAQ:MEDS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $2.50 and a low of $1.75, we find $2.50. Given the previous closing price of $0.29, this indicates a potential upside of 762.07 percent. MEDS stock price is now -36.31% away from the 50-day moving average and -71.32% away from the 200-day moving average. The market capitalization of the company currently stands at $3.84M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
It has been rated a hold by 0 analysts and a buy by 3. Brokers who have rated the stock have averaged $2.25 as their price target over the next twelve months.
.
In other news, Fell Donald G., Director bought 1,500 shares of the company’s stock on Aug 25. The stock was bought for $1,620 at an average price of $1.08. Upon completion of the transaction, the Director now directly owns 21,139 shares in the company, valued at $7821.43. An SEC document containing details of the transaction can be found on the SEC’s website. On May 20, CEO AJJARAPU SURENDRA K bought 10,000 shares of the business’s stock. A total of $130,000,000 was incurred on buying the stock at an average price of $13000.00. This leaves the insider owning 222,500 shares of the company worth $82325.0. A total of 27.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MEDS stock. A new stake in TRxADE HEALTH Inc. shares was purchased by TWO SIGMA SECURITIES, LLC during the first quarter worth $6,000. In total, there are 14 active investors with 6.20% ownership of the company’s stock.
TRxADE HEALTH Inc. (NASDAQ: MEDS) opened at $0.2900 on Monday. During the past 12 months, TRxADE HEALTH Inc. has had a low of $0.27 and a high of $3.47. As of last week, the company has a debt-to-equity ratio of 0.36, a current ratio of 1.20, and a quick ratio of 1.10. The fifty day moving average price for MEDS is $0.5810 and a two-hundred day moving average price translates $1.2900 for the stock.
The latest earnings results from TRxADE HEALTH Inc. (NASDAQ: MEDS) was released for Jun, 2022. According to the Pharmaceutical Retailers Company, earnings per share came in at -$0.13, missing analysts’ expectations of -$0.08 by -0.05. This compares to -$0.16 EPS in the same period last year. The net profit margin was -29.50% and return on equity was -135.10% for MEDS. The company reported revenue of $2.4 million for the quarter, compared to $2.55 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.88 percent. For the current quarter, analysts expect MEDS to generate $3.3M in revenue.
TRxADE HEALTH Inc.(MEDS) Company Profile
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O’ Lakes, Florida.
